A

Assembly Biosciences
D

ASMB

14.610
USD
0.28
(1.97%)
مغلق
حجم التداول
428
الربح لكل سهم
-6
العائد الربحي
-
P/E
-2
حجم السوق
92,865,338
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    ABBV
    ABBV
    -3.460
    (-2.00%)
    169.130 USD
    AMGN
    AMGN
    -1.26
    (-0.46%)
    273.59 USD
    BMY
    BMY
    0.025
    (0.04%)
    57.075 USD
    GILD
    GILD
    0.070
    (0.08%)
    93.020 USD
    I
    INO
    0.06500
    (2.96%)
    2.26000 USD
    LLY
    LLY
    11.37
    (1.53%)
    753.86 USD
    MRK
    MRK
    -0.560
    (-0.58%)
    95.670 USD
    N
    NVAX
    0.02500
    (0.28%)
    8.84500 USD
    PFE
    PFE
    -0.621
    (-2.33%)
    26.015 USD
    REGN
    REGN
    -7.47
    (-1.09%)
    679.85 USD
    المزيد
الأخبار
المقالات

العنوان: Assembly Biosciences

القطاع: Healthcare
الصناعة: Biotechnology
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenueis generated from the HBV cure program.